Hign dose Daunorubicin

Phase 3Small molecule

AAsan Medical Center

Hign dose Daunorubicin is one of 22 small molecule programs targeting Prospective. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProspectiveEnrolling by invitation

ProspectivePhase 3

Enrolling by invitation

Competition

Competitive Landscape

31 competitors in Prospective

#DrugCompanyPhaseTrials

Tnkase

Roche

Approved

1 2

Zeposia

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 3

Venclexta

AbbVie

Phase 3

2 4

Nexavar

Bayer

Phase 3

2 5

Cytosar

Teva

Phase 3

1 6

Xiidra

BBausch Health Americas, Inc.

Approved

1 7

Mulpleta

IItalian Network for Tumor Biotherapy Foundation

Approved

1 8

Beyfortus

BeiGene

Phase 2

1 9

Imbruvica

PPharmacyclics LLC.

Phase 2

1 10

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prospective1 trial

A Prospective Randomized Comparison of HDAC Vs AD in the Induction Chemothrapy for AML.

Enrolling by invitation·—·Phase 3·NCT03507842·380 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hign dose Daunorubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hign dose Daunorubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hign dose Daunorubicin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Asan Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAsan Medical Center

Hign dose Daunorubicin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prospective1 trial

References

Drug Info

Quick Facts

Related News